Compare Incyte Corporation (INCY) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Direxion Daily S&P 500 Bull 3X Shares trades at $270.89. The key difference: Incyte Corporation is trading nearer its 52-week high, Direxion Daily S&P 500 Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| INCY | SPXL | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $288.04 |
52-Week Low | $67.38 | $170.20 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SPXL, a leveraged ETF tracking the S&P 500, trades at $264.57, down 0.44% on the day amid broader market weakness. Technical indicators signal a bearish bias with moving averages pointing lower, though oscillators remain neutral. Recent news highlights concerns about S&P 500 valuation and AI-driven concentration risks, with the index facing pressure from chip stock declines and macroeconomic uncertainty.
The outlook hinges on S&P 500 performance, with earnings season and economic data as key catalysts. Risks include market overvaluation and sector concentration, but analyst targets suggest potential upside if bullish forecasts materialize. Investors must weigh leveraged exposure against volatility and broader index trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
